4D Molecular Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
FDMT
4D Molecular Therapeutics, Inc. Common Stock
$15.04 -4.96%
VS MRNAModerna, Inc. Common Stock
$132.55 -8.67%
4D Molecular Therapeutics, Inc. Common Stock and Moderna, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| FDMT | MRNA | |
|---|---|---|
| Market Cap | $874.52 million | $57.94 billion |
| Revenue (TTM) | $92.01 million | $2.23 billion |
| Net Income (TTM) | $-179,175,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| FDMT | MRNA | |
|---|---|---|
| Price / Book | 2.15 | 8.57 |
| Price / Sales | 9.50 | 26.01 |
FDMT leads on 2 of 2 valuation factors.
Profitability
| FDMT | MRNA | |
|---|---|---|
| Net Margin | -194.74% | -141.43% |
| Return on Equity | -43.95% | -46.61% |
FDMT and MRNA split the profitability factors evenly.
Risk & Sentiment
| FDMT | MRNA | |
|---|---|---|
| Short Interest | 0.41% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: FDMT overview, FDMT financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.